Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel
June 15 2022 - 08:00AM
Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI),
a leading point-of-care diagnostic company focused on
infectious diseases, today announced the launch of its
direct-to-consumer commercial channel for the third-party SCoV-2 Ag
Detect Self-Test in the U.S. market. In addition, Chembio is
expanding distribution of its SURE CHECK HIV Self-Test to consumers
in Brazil and the United Kingdom by broadening the test kit’s
existing Over-the-Counter (OTC) availability in national pharmacy
chains.
“We are excited to expand patient access to rapid, accurate and
easy to use at home diagnostics across the United States, Brazil
and the United Kingdom,” said Richard Eberly, Chembio’s Chief
Executive Officer and President. “We are now offering the SCoV-2 Ag
Detect Self-Test via our distribution network and directly through
Chembio in the US. In addition, we are now offering our SURE CHECK
HIV Self-Test through e-commerce platforms in the UK and Brazil.
This commercial expansion increases our addressable market and is
intended to enable deeper penetration of the market as at home
testing volumes continue to grow. This initiative directly aligns
with our goal to focus on higher margin business in growing markets
under our Global Competitiveness Program.”
Customers can obtain more information related to the SCoV-2 Ag
Detect Self-Test and the SURE CHECK HIV Self-Test at
www.chembio.com.
About SCoV-2 Ag Detect Self-TestThe SCoV-2 Ag
Detect Self-Test will launch in the U.S. in June, with distributors
servicing the OTC market and Chembio simultaneously beginning to
accept direct customer orders. The SCoV-2 Ag Detect™ Self-Test,
manufactured by InBios International, Inc., is a rapid immunoassay
test for the detection of SARS-CoV-2 antigens that provides results
in 20 minutes from a nasal swab and requires no instrumentation.
The product is cleared for OTC use under an Emergency Use
Authorization issued by the U.S. Food and Drug Administration.
About SURE CHECK HIV Self-TestThe
direct-to-consumer initiative for the Chembio’s SURE CHECK HIV
Self-Test will launch in Brazil through a third-party e-commerce
partner and in the United Kingdom via Amazon in July. The SURE
CHECK HIV Self-Test is a single-use in-vitro diagnostic self-test
that detects antibodies to HIV-1 and HIV-2 from a 2.5 µl
fingerstick whole blood sample. The SURE CHECK HIV Self-Test is
currently being marketed in Brazil under ANVISA approval and in the
United Kingdom under a CE Mark.
About Chembio DiagnosticsChembio is a leading
diagnostics company focused on developing and commercializing
point-of-care tests used to detect and diagnose infectious
diseases, including sexually transmitted disease, insect vector and
tropical disease, COVID-19 and other viral and bacterial
infections, enabling expedited treatment. Coupled with Chembio’s
extensive scientific expertise, its novel DPP technology offers
broad market applications beyond infectious disease. Chembio’s
products are sold globally, directly and through distributors, to
hospitals and clinics, physician offices, clinical laboratories,
public health organizations, government agencies, and consumers.
Learn more at www.chembio.com.
DPP and SURE CHECK are Chembio’s registered trademarks, and the
Chembio logo is Chembio’s trademark. For convenience, these
trademarks appear in this release without ® or ™ symbols, but that
practice does not mean that Chembio will not assert, to the fullest
extent under applicable law, its rights to the trademarks.
Contact:Philip TaylorGilmartin Group(415)
937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2023 to Mar 2024